MIRM Earnings Prediction
The chart below shows how MIRM performed 10 days before and after its earnings report, based on data from the past quarters. Typically, MIRM sees a +0.36% change in stock price 10 days leading up to the earnings, and a -1.97% change 10 days following the report. On the earnings day itself, the stock moves by -1.27%. This data can give you a slight idea of what to expect for the next quarter's release.
MIRM Key Earning Data
2024/Q4
Year Over Year
Quarter Over Quarter
Total Revenue
99.41M
42.93%
10.00%
Gross Margin
77.09%
20.40%
0.14%
Operating Margin
-24.36%
-48.00%
73.63%
Net Margin
-23.93%
-53.33%
51.94%
EPS
-0.49
-35.53%
63.33%
No Data Available
MIRM Earnings Analysis
Mirum Pharmaceuticals Inc Corporation (MIRM.O) Earnings Conference Call
Positive
Sales Exceed Guidance: Mirum Pharmaceuticals achieved total net product sales of $336.4 million in 2024, exceeding the upper-end of their revised guidance range.
Strong Sales Growth: LIVMARLI generated total net product sales of $213 million in 2024, with strong growth driven by new patient starts and international uptake.
FDA Approval for CTX Treatment: The FDA approved CTEXLI for cerebrotendinous xanthomatosis (CTX), allowing for promotional efforts to reach patients in this under-diagnosed condition.
Projected Revenue Increase: The company expects to add close to $100 million to their top-line in 2025, with anticipated net product sales between $420 million and $435 million.
LIVMARLI Label Expansion: Mirum expanded LIVMARLI's label with its approval for PFIC in both the US and Europe, enhancing its market potential.
Breakthrough Designation Achieved: Positive interim results for Volixibat in both VISTAS PSC and VANTAGE PBC studies were reported, leading to breakthrough designation in PBC.
LIVMARLI Enrollment Progress: The Phase 3 EXPAND study of LIVMARLI is on track to complete enrollment in 2026, targeting cholestatic pruritus, a significant growth opportunity.
Phase 2 Study Initiation: MRM-3379 for Fragile X syndrome is set to initiate a Phase 2 study this year, addressing a high unmet need in rare genetic neurology.
Strong Financial Position: The company ended 2024 with cash, cash equivalents, and investments of $293 million, indicating a strong financial position.
Positive Cash Flow Outlook: Mirum expects to maintain positive cash flow in 2025, supported by their strong performance and well-funded resources.
Negative
High Operating Expenses: Total operating expenses for 2024 were $424.5 million, which is significantly high and includes substantial R&D and SG&A expenses.
Stock-Based Compensation Impact: Despite a strong revenue growth, the company incurred a non-cash stock-based compensation expense of $48.4 million, which could impact profitability.
Sales Increase vs. Expenses: The company reported a net product sales increase, but the overall operating expenses outpaced revenue growth, indicating potential financial strain.
License Payment Impact: The upfront payment of $7.5 million for the MRM-3379 license adds to the financial burden, raising concerns about cash flow management.
Cash Flow and Revenue Risks: While the company expects positive cash flow in 2025, the reliance on continued revenue growth to sustain this is a risk, especially in the competitive pharmaceutical market.
MIRM FAQs
How does MIRM typically perform around its earnings report dates?
Is Mirum Pharmaceuticals Inc (MIRM) Q4 2024 Earnings Call Summary positive or negative?
How can historical earnings data help predict future stock performance?
MIRM Earning Call Sentiment
Mirum Pharmaceuticals, Inc. (MIRM) Q4 2024 Earnings Call Transcript
MIRM.O
-0.63%Positive
The earnings call reveals significant positive factors: a strong increase in net product sales, positive operating cash flow, and increased revenue guidance. The FDA's breakthrough designation and pipeline expansion are promising for future growth. The Q&A section shows confidence in capital allocation and market penetration. Although there are risks in regulatory issues and competitive pressures, the overall sentiment is positive, with robust financial metrics and optimistic guidance. Given the company's small market cap, the stock is likely to react positively, with a predicted increase of 2% to 8% over the next two weeks.
